Ryaltris Patent Expiration

Ryaltris is a drug owned by Glenmark Specialty Sa. It is protected by 14 US drug patents filed from 2022 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 03, 2038. Details of Ryaltris's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11679210 Dispensing device and pharmaceutical composition for the treatment of rhinitis
Sep, 2038

(13 years from now)

Active
US10765686 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(9 years from now)

Active
US10758550 Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Sep, 2034

(9 years from now)

Active
US10646500 Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Sep, 2034

(9 years from now)

Active
US11400101 Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Sep, 2034

(9 years from now)

Active
US10016443 Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Sep, 2034

(9 years from now)

Active
US10517880 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(9 years from now)

Active
US9750754 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(9 years from now)

Active
US9078923 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(9 years from now)

Active
US10561672 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(9 years from now)

Active
US9370483 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(9 years from now)

Active
US10376526 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(9 years from now)

Active
US10548907 Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Sep, 2034

(9 years from now)

Active
US9937189 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(9 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ryaltris's patents.

Given below is the list of recent legal activities going on the following patents of Ryaltris.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 21 Feb, 2024 US10765686
Payment of Maintenance Fee, 4th Year, Large Entity 14 Feb, 2024 US10758550
Payment of Maintenance Fee, 8th Year, Large Entity 06 Dec, 2023 US9370483
Payment of Maintenance Fee, 4th Year, Large Entity 25 Oct, 2023 US10646500
Payment of Maintenance Fee, 4th Year, Large Entity 02 Aug, 2023 US10561672
Post Issue Communication - Certificate of Correction 31 Jul, 2023 US10016443
Payment of Maintenance Fee, 4th Year, Large Entity 19 Jul, 2023 US10548907
Electronic Review 29 Jun, 2023 US10016443
Email Notification 29 Jun, 2023 US10016443
Mail Pet Dec Routed to Certificate of Corrections Branch 28 Jun, 2023 US10016443


FDA has granted several exclusivities to Ryaltris. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Ryaltris, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Ryaltris.

Exclusivity Information

Ryaltris holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2025. Details of Ryaltris's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 13, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Ryaltris's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Ryaltris's generic, the next section provides detailed information on ongoing and past EP oppositions related to Ryaltris patents.

Ryaltris's Oppositions Filed in EPO

Ryaltris has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 29, 2022, by Ter Meer Steinmeister & Partner Patentanwälte Mbb. This opposition was filed on patent number EP14781946A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP14781946A Mar, 2022 Ter Meer Steinmeister & Partner Patentanwälte mbB Granted and Under Opposition


US patents provide insights into the exclusivity only within the United States, but Ryaltris is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ryaltris's family patents as well as insights into ongoing legal events on those patents.

Ryaltris's Family Patents

Ryaltris has patent protection in a total of 32 countries. It's US patent count contributes only to 20.8% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Ryaltris.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Ryaltris's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 03, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Ryaltris Generics:

There are no approved generic versions for Ryaltris as of now.





About Ryaltris

Ryaltris is a drug owned by Glenmark Specialty Sa. It is used for treating seasonal allergic rhinitis through nasal administration of a combination of olopatadine hydrochloride and mometasone furoate. Ryaltris uses Mometasone Furoate; Olopatadine Hydrochloride as an active ingredient. Ryaltris was launched by Glenmark Speclt in 2022.

Approval Date:

Ryaltris was approved by FDA for market use on 13 January, 2022.

Active Ingredient:

Ryaltris uses Mometasone Furoate; Olopatadine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Mometasone Furoate; Olopatadine Hydrochloride ingredient

Treatment:

Ryaltris is used for treating seasonal allergic rhinitis through nasal administration of a combination of olopatadine hydrochloride and mometasone furoate.

Dosage:

Ryaltris is available in spray, metered form for nasal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.025MG/SPRAY;0.665MG/SPRAY SPRAY, METERED Prescription NASAL